Osteoarthritis Clinical Trials Near You

Osteoarthritis (OA) trials in 2026 are shifting from symptom management toward genuine disease modification. Anti-nerve growth factor (anti-NGF) antibodies (tanezumab, fasinumab) provided dramatic pain relief in late-stage trials, though safety signals around rapidly progressive joint destruction led to restricted development. Modified dosing protocols and patient selection criteria are being tested to preserve the analgesic benefit while managing this risk.

Injectable disease-modifying therapies are emerging: lorecivivint (a Wnt pathway inhibitor) aims to slow cartilage degradation and promote cartilage growth. Sprifermin (fibroblast growth factor 18) showed cartilage thickness increase in Phase 2 trials — the first time any therapy demonstrated structural cartilage improvement on MRI.

Platelet-rich plasma (PRP), hyaluronic acid, and stem cell injections are in rigorous comparative trials to establish which regenerative approaches provide genuine benefit beyond placebo. Autologous chondrocyte implantation and matrix-associated stem cell therapy target localized cartilage defects.

Weight management trials specifically for knee OA are testing whether GLP-1 agonist-mediated weight loss (10–15%) translates to meaningful joint symptom improvement and structural disease slowing, alongside joint-specific exercise programs.

For severe OA, robotic-assisted partial knee replacement and patient-specific 3D-printed implant trials are aiming to improve outcomes and longevity of joint replacement surgery.

Patient considerations: OA trials use X-ray or MRI to confirm joint space narrowing and Kellgren-Lawrence grading. Expect regular pain assessments (WOMAC, VAS scores), physical function tests, and imaging. Most trials focus on knee or hip OA — hand OA has a smaller but growing trial pipeline. A washout period from NSAIDs or corticosteroid injections (typically 4–8 weeks) is usually required.